Radiopharma company Lantheus is looking to build up its portfolio through a collaboration with Perspective Therapeutics. By handing Perspective $28 million upfront, Lantheus has the exclusive option to secure a licensing deal for an alpha-targeted therapy in neuroendocrine tumors.
As for Seattle-based Perspective, it is taking over Lantheus’ radiopharma manufacturing facility in Somerset, NJ for an undisclosed price. In August last year, Lantheus said it was winding down this site, according to an SEC filing. Lantheus is in the radioactive diagnostic and imaging space, with several therapeutic assets in its research pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.